阿托伐他汀对急性冠脉综合征患者血清MIF、MMP-1及hs-CRP的影响

Effect of Atorvastatin on Serum MIF,MMP-1 and hs-CRP in Patients with Acute Coronary Syndrome

目的探讨阿托伐他汀对急性冠脉综合征(ACS)患者血清MIF、MMP-1及hs-CRP的影响。方法 将170例冠心病患者分为2组:ACS组120例,稳定性心绞痛(SAP)组50例,另选同期40例冠状动脉造影正常者为对照组。同时随机将ACS患者分为阿托伐他汀组和常规治疗组各60例。采用酶联免疫吸附法(ELISA)测定血清MIF、MMP-1水平,用超敏乳胶增强免疫比浊法测定血清hs-CRP水平,比较各组血清MIF、MMP-1、hs-CRP水平的变化。结果ACS组血清MIF、MMP-1、hs-CRP水平显著高于SAP组和对照组(P<0.01)。阿托伐他汀组治疗后与治疗前及常规治疗组治疗后比较,血清MIF、MMP-1、hs-CRP水平明显下降(P<0.01或0.05)。结论阿托伐他汀可降低ACS患者血清MIF、MMP-1、hs-CRP水平,减少冠状动脉粥样斑块基质成分的降解和炎症反应,增强动脉粥样硬化斑块的稳定性。

Objective To explore the effect of atorvastatin on serum levels of macrophage migration inhibitory factor（MIF）,matrix metalloproteinase-1（MMP-1） and high sensitive C-reactive protein between（hs-CRP） in patients with acute coronary syndrome（ACS）. Methods Totally 170 patients with coronary heart disease were divided into two groups： ACS group（n=120） and stable angina pectoris（SAP） group（n=50）.40 individuals with normal coronary angiography were selected as control group.At the same time,120 patients with ACS were randomly divided into atorvastatin group （n=60） and conventional-treated group（n=60）.Serum levels of MIF and MMP-1 were measured by enzyme-linked immunosorbent assay（ELISA）.Serum hs-CRP levels were detected by immune nephelometry.The change of serum MIF,MMP-1 and hs-CRP levels was compared among the groups. Results Serum levels of MIF,MMP-1 and hs-CRP in ACS group were significantly higher than those in SAP group and control group（P0.01）.After the treatment,serum levels of MIF,MMP-1 and hs-CRP in atorvastatin group and conventional-treated group were significantly decreased as compared with those in the two groups before the treatment（P0.01,P0.05）. Conclusions Atorvastatin can decrease serum MIF,MMP-1 and hs-CRP levels in patients with ACS,which contributes to attenuation of matrix degradation and inflammation response and results in an increase of stability of atherosclerosis plaque.